PET in Hepatobiliary-Pancreatic Tumors
Primary liver cancer is a relatively uncommon entity, accounting for only 1–2% of malignant tumors, while cholangiocarcinoma is even rarer. However, in parts of Africa and Asia these tumors may constitute up to 20–30% of all malignancies. Other benign and malignant hepatobiliary-pancreatic tumors are very rare; they include hepatoblastoma in infancy and early childhood, hemangiomas (the most common benign tumors), and angiosarcomas (vascular tumors). Hepatic adenomas, although also rare, may occur particularly in women taking oral contraceptives. In the USA, pancreatic cancer has an incidence of 12 per 100,000 men and women per year, and cancer of the pancreas is the third most common malignancy of the gastrointestinal tract and the fifth most common cause of cancer-related mortality. Islet cell tumors constitute 5–10% of pancreatic tumors and are usually referred to as neuroendocrine tumors of the pancreas.
KeywordsPositron Emission Tomography Pancreatic Cancer Autoimmune Pancreatitis Islet Cell Tumor Compute Tomography Report
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Bang S, Chung HW, Park SW et al (2006) The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. J Clin Gastroenterol 40:923–929CrossRefPubMedGoogle Scholar
Breitenstein S, Apestegui C, Clavien PA (2008) Positron emission tomography (PET) for cholangiocarcinoma. HPB (Oxford) 10:120–121Google Scholar
Dierckx R, Maes A, Peeters M, Van De Wiele C (2009) FDG PET for monitoring response to local and locoregional therapy in HCC and liver metastases. Q J Nucl Med Mol Imaging 53:336–342PubMedGoogle Scholar
Eckel F, Herrmann K, Schmidt S et al (2009) Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F-fluorothymidine. J Nucl Med 50:1441–1447CrossRefPubMedGoogle Scholar
Higashi T, Saga T, Nakamoto Y et al (2003) Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) — usefulness and limitations in “clinical reality”. Ann Nucl Med 17:261–279CrossRefPubMedGoogle Scholar
Kauhanen SP, Komar G, Seppänen MP et al (2009) A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann Surg 250:957–963CrossRefPubMedGoogle Scholar
Kornberg A, Küpper B, Thrum K et al (2009) Increased 18F-FDG uptake of hepatocellular carcinoma on positron emission tomography independently predicts tumor recurrence in liver transplant patients. Transplant Proc 41:2561–2563CrossRefPubMedGoogle Scholar
Lee TY, Kim MH, Park do H et al (2009) Utility of 18F-FDG PET/CT for differentiation of autoimmune pancreatitis with atypical pancreatic imaging findings from pancreatic cancer. Am J Roentgenol 193:343–348CrossRefGoogle Scholar
Pakzad F, Groves AM, Ell PJ et al (2006) The role of positron emission tomography in the management of pancreatic cancer. Semin Nucl Med 36:248–256CrossRefPubMedGoogle Scholar
Salem N, Kuang Y, Wang F et al (2009) PET imaging of hepatocellular carcinoma with 2-deoxy-2[18F]fluoro-D-glucose, 6-deoxy-6[18F] fluoro-D-glucose, [1-11C]-acetate and [N-methyl-11C]-choline. Q J Nucl Med Mol Imaging 53: 144–156PubMedGoogle Scholar
Seo S, Hatano E, Higashi T et al (2008) Fluorine-18 fluorodeoxy-glucose positron emission tomography predicts lymph node metastasis, P-glycoprotein expression, and recurrence after resection in mass-forming intrahepatic cholangiocarcinoma. Surgery 143:769–777CrossRefPubMedGoogle Scholar
© Springer Verlag Italia 2010